Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HOWLthis companyWerewolf Therapeutics, Inc.	$1.02	-0.48×	1.18×	0×	0.36×	-2.6%	0.0%	0.0%	0.0%	-245.2%	-173.4%	-206.8%	0.38×	0.9×	-11.5×	1.62×	0.0%	4	-26.12	2	C+
ACETAdicet Bio, Inc.	$3.06	-0.5×	0.36×	0×	-0.31×	-8.6%	0.0%	0.0%	0.0%	-73.4%	-70.2%	-167.1%	0.09×	0.22×	-3,392.06×	7.47×	0.0%	1	-6.93	3	B-
CUECue Biopharma, Inc.	$18.95	-1.09×	1.09×	1.05×	-0.24×	-850.1%	100.0%	-96.6%	-96.9%	-100.6%	-86.6%	-75.6%	0.16×	0.93×	-74.29×	2.74×	0.0%	2	-30.14	1	D+
INMBINmune Bio, Inc.	$1.15	-0.84×	1.76×	829.46×	-0.39×	-44.6%	100.0%	-61738.0%	-91866.0%	-195.3%	-125.7%	-57.0%	0.04×	0.52×	0×	3.55×	0.0%	1	-9.17	2	C+
LITSLite Strategy, Inc.	$1.03	-0.45×	0.77×	0×	-2.13×	-83.7%	0.0%	0.0%	0.0%	-170.9%	-29.5%	-28.6%	0×	0.47×	0×	5.74×	0.0%	1	0.13	2	C
NRXPNRx Pharmaceuticals, Inc.	$2.37	-2.02×	-3.64×	47.35×	-1.83×	-67.8%	58.8%	-1324.4%	-2336.5%	179.6%	106.0%	-24.3%	-0.04×	0.26×	-24.18×	0.31×	0.0%	4	-13.9	2	C+
Peer median	—	-0.84×	0.77×	1.05×	-0.39×	-67.8%	58.8%	-96.6%	-96.9%	-100.6%	-70.2%	-57.0%	0.04×	0.47×	-24.18×	3.55×	0.0%	1	-9.17	2	—